Acrobiosystems for English
icon_bulk_orderBulk inquiry/Quick order
0
There is no goods in the shopping cart !
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z 0-9
Your Position: Home > Protein > CD30 > CD0-HF250

FITC-Labeled Human CD30 / TNFRSF8 Protein, Fc Tag

Order Now

  • Synonym
    TNFRSF8,CD30,D1S166E,Ki-1
  • Source
    FITC-Labeled Human CD30, His Tag (Cat. No. CD0-HF250) is expressed from human HEK293 cells. It contains AA Phe 19 - Lys 379 (Accession # NP_001234.2). It is the FITC labeled form of Human CD30, His Tag (Cat. No.CD0-H5250).
    Predicted N-terminus: Phe 19
  • Molecular Characterization
    Online(Phe 19 - Lys 379) NP_001234.2

    This protein carries a human IgG1 Fc tag at the C-terminus.

    The protein has a calculated MW of 64.6 kDa. The protein migrates as 70-110 kDa under reducing (R) condition (SDS-PAGE) due to glycosylation.

  • Conjugate

    FITC

    Excitation source: 488 nm spectral line, argon-ion laser

    Excitation Wavelength: 488 nm

    Emission Wavelength: 535 nm

  • Labeling
    The primary amines in the side chains of lysine residues and the N-terminus of the protein are conjugated with FITC using standard chemical labeling method. The residual FITC is removed by molecular sieve treatment during purification process.
  • FITC:Protein Ratio
    The FITC to protein molar ratio is 2-4.
  • Endotoxin
    Less than 1.0 EU per μg by the LAL method.
  • Purity

    >90% as determined by SDS-PAGE.

  • Formulation

    Lyophilized from 0.22 μm filtered solution in PBS, pH7.4. Normally trehalose is added as protectant before lyophilization.

    Contact us for customized product form or formulation.

  • Reconstitution

    Please see Certificate of Analysis for specific instructions.

    For best performance, we strongly recommend you to follow the reconstitution protocol provided in the CoA.

  • Storage

    For long term storage, the product should be stored at lyophilized state at -20°C or lower.

    Please protect from light and avoid repeated freeze-thaw cycles.

    This product is stable after storage at:

    1. -20°C to -70°C for 12 months in lyophilized state;
    2. -70°C for 3 months under sterile conditions after reconstitution.
SDS-PAGE
FITC-Labeled Human CD30, Fc Tag (Cat. No. CD0-HF250) SDS-PAGE gel

FITC-Labeled Human CD30, Fc Tag on SDS-PAGE under reducing (R) condition. The gel was stained with Coomassie Blue. The purity of the protein is greater than 90%.

Bioactivity-ELISA
FITC-Labeled Human CD30, Fc TagFITC-Labeled Human CD30, Fc Tag (Cat. No. CD0-HF250) ELISA bioactivity

Immobilized Monoclonal Anti-Human CD30 Human Antibody, Human IgG1 at 1 μg/mL (100 μL/well) can bind FITC-Labeled Human CD30, Fc Tag (Cat. No. CD0-HF250) with a linear range of 0.08-1.3 μg/mL (QC tested).

FITC-Labeled Human CD30, Fc TagFITC-Labeled Human CD30, Fc Tag (Cat. No. CD0-HF250) ELISA bioactivity

Immobilized Human CD30 Ligand, Mouse IgG2a Fc Tag, low endotoxin (Cat. No. CDL-H525b) at 2 μg/mL (100 μL/well) can bind FITC-Labeled Human CD30, Fc Tag (Cat. No. CD0-HF250) with a linear range of 0.2-1.3 μg/mL (Routinely tested).

  • Background
    Human CD30 is also known as TNFRSF8, is a cell membrane protein of the tumor necrosis factor receptor family and tumor marker. TNFRSF-8 is expressed by activated, but not by resting, T and B cells. Also, CD30 is expressed on classical Hodgkin Lymphoma cells together with CD15. CD30 is the receptor for TNFSF8/CD30L. CD30 can interact with TRAF2 and TRAF5, and mediate the signal transduction that leads to the activation of NF-kappa-B. TNFRSF8 may play a role in the regulation of cellular growth and transformation of activated lymphoblasts. TNFRSF8 is a positive regulator of apoptosis, and also has been shown to limit the proliferative potential of autoreactive CD8 effector T cells and protect the body against autoimmunity.
  • Clinical and Translational Updates
      
  • Please contact us via TechSupport@acrobiosystems.com if you have any question on this product.

Comments (0)


ETA of in-stock products: 2 business days

Price(USD) : $319.00

Price(USD) : $2180.00

Promotion & Exhibitions



Drug Development Status

  • Number of Launched Drugs:1 Details
  • Number of Drugs in Clinical Trials:21 Details
  • Latest Research Phase:Approved

Datasheet & Documentation

Request for DMF
DMF (Drug Master File)

Related Products

New Product Launch

Questions & Comments

This web search service is supported by Google Inc.

totop
Call us
Call us
North America:
+1 800-810-0816 (Toll Free)
Asia & Pacific:
+86 400-682-2521
Fax
Fax
+1 888-377-6111
Address
Address
1 Innovation Way, Newark, DE 19711, USA

Leave a message